Quebec City-based Medicago Inc is investing $4 million in its pilot production facility and hiring 20 new staff this year to accelerate preclinical and clinical development timelines for future drug candidates. A developer of vaccines based on its proprietary manufacturing technologies, Medicago will direct investment towards capital expenditures, labour costs and preclinical studies for a rabies vaccine. The investment builds on a $1.77-million award from the Quebec Consortium for Drug Discovery to develop VLP Express, an automated high-throughput platform for the rapid expression, purification and testing of virus-like particles....